Immunotherapy earns its spot in the ranks of cancer therapy.
about
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyAnti-tumor immunity: myeloid leukocytes control the immune landscapePathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancerCombinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinMaintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysisHCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinomaCombined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.VISTA Regulates the Development of Protective Antitumor Immunity.Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expressionSpecific increase in potency via structure-based design of a TCR.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer.Immune checkpoint receptors in regulating immune reactivity in rheumatic disease.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor AntigenSplenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway BlockadeMultiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironmentImmuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer.Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.SHP-1 phosphatase activity counteracts increased T cell receptor affinity.Porphyromonas gingivalis: keeping the pathos out of the biont.Using macrophage activation to augment immunotherapy of established tumours.Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapyThe ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Cancer as an immune-mediated disease.GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment.The confluence of radiotherapy and immunotherapy.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
P2860
Q26850218-AC0FD0E7-7EE5-42A5-ACF2-549466815AA9Q28076473-8A34B205-1BE1-481E-A845-AD865078E43BQ28390573-E7D2E47E-1132-4F22-8EC2-4B03D249AD95Q28392626-566E10D5-2738-4D19-BCE6-70B213CF3CFCQ28537820-A1486B76-6A99-40FD-8E2E-5A9098044261Q30317446-A2161A4F-2BFA-4447-8B3C-31CB7A4560B6Q31082473-BCA58DBE-1CC2-4C02-97F3-B2521986F7DEQ33779140-45F308E9-4BED-4EBC-8D6A-51A49304FEE3Q33926200-9B999632-71A7-4F7C-8AC2-2DAF47CC13FCQ33978040-5F4CA493-92E2-4529-83F2-5B1083F2A99FQ34240499-F8FB5B98-508B-40EF-AF40-6579C4E4EAC5Q34383054-F5642CF2-54DC-4198-98E8-89B114CE2311Q34658452-AC8B4C5D-7D45-4F8C-959F-916F6FCA3F80Q34734013-05DD3476-8D7D-4CB9-875C-2E2D8C5B6EEBQ34816275-163CC88C-90AE-4989-9EF3-1603C563F290Q34897654-5D6CC39D-1038-43BC-9195-22A0539A9913Q35107110-9396309A-1CD1-41B5-AFEC-8285E8AE3391Q35328111-EB1ACE59-B43E-4619-8C84-BC749AB15F02Q35799198-E3812FEA-1520-40F9-B00A-9CB90149C0AAQ36021317-34F5943E-1EEC-4BE2-914A-E2CCDCD6B6D4Q36177909-DACE947A-AACE-4364-8A10-D1EBAE627194Q36243616-86B3B80B-A05A-40ED-B057-6A58471D0961Q36248464-3D14A7CB-8FE9-4611-8CDC-0997F635A4B4Q36269232-F3C6E660-6B05-4256-989E-1ABD6EB2D990Q36638160-C2469D9F-1AEC-45BD-A078-93A36A585BD4Q36743392-EAD57925-93A1-4C46-8FBD-63476078BA0AQ36747346-225FC44B-93AB-4EA9-81A6-97F4359EB5CDQ36869774-19400DB0-68BA-4C22-8965-E7504B06EEBCQ36928855-4E1B0290-F93D-4868-B55F-D0F7CE2D435FQ36955437-AD3A32AB-B71C-4F6F-BE71-7A8B7C54D9CBQ37012561-75BB64F5-5AE6-4F45-B415-DDFD08B9581CQ37068312-06EDB129-7171-4F75-A5E6-36E91B7D2484Q37080218-6FCD10DD-DFB4-441A-A7CA-0E136570B48DQ37169908-28964A79-BABE-429F-A5CC-97F8B8ABB6F1Q37694431-9D921BF1-FA75-4065-A8C0-091FF6A5A983Q38054113-010462D7-35F6-4822-870A-B33D8D6215BDQ38060734-07F3BC89-8B21-4C50-85C2-0280BDBDAC4CQ38082845-2D5BCF28-89ED-496A-9819-AE69176E2486Q38094625-74F82A60-E30A-4ABC-8333-9C63E0BBF686Q38108353-304A1908-E9B8-4B89-A4AC-4C10876105A5
P2860
Immunotherapy earns its spot in the ranks of cancer therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunotherapy earns its spot in the ranks of cancer therapy.
@en
type
label
Immunotherapy earns its spot in the ranks of cancer therapy.
@en
prefLabel
Immunotherapy earns its spot in the ranks of cancer therapy.
@en
P2860
P356
P1476
Immunotherapy earns its spot in the ranks of cancer therapy.
@en
P2093
Charles Drake
Drew Pardoll
P2860
P304
P356
10.1084/JEM.20112275
P407
P577
2012-02-01T00:00:00Z